SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-006322
Filing Date
2022-01-11
Accepted
2022-01-11 08:00:56
Documents
12
Period of Report
2022-01-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d273838d8k.htm   iXBRL 8-K 31567
  Complete submission text file 0001193125-22-006322.txt   151331

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA amrx-20220111.xsd EX-101.SCH 2885
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE amrx-20220111_lab.xml EX-101.LAB 17373
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amrx-20220111_pre.xml EX-101.PRE 10948
6 EXTRACTED XBRL INSTANCE DOCUMENT d273838d8k_htm.xml XML 3250
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 22522778
SIC: 2834 Pharmaceutical Preparations